Reviva Pharmaceuticals' Schizophrenia Candidate Shows Favorable Drug-Drug Interaction Data

Reviva Pharmaceuticals Holdings Inc RVPH has announced data from its clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects.
The CYP3A4 enzyme is pivotal in helping the body metabolize and remove small foreign molecules and is primarily found in the liver and intestine.
Brilaroxazine is a serotonin/dopamine modulator in late-stage clinical development for schizophrenia.
A CYP3A4 inhibitor, itraconazole, slightly increased brilaroxazine Cmax, AUClast, and AUCinf by 6, 16 and 13%, respectively, in healthy volunteers (N=11).
Similarly, a CYP3A4 inducer, phenytoin, in healthy volunteers (N=16) decreased brilaroxazine Cmax, AUClast, and AUCinf by 33, 56, and 53%, respectively.
Brilaroxazine's DDI study found no clinically significant interaction when combined with a CYP3A4 inhibitor.
Brilaroxazine is currently being evaluated in RECOVER Phase 3 trial to assess the safety and efficacy of brilaroxazine in approximately 400 patients with acute schizophrenia compared to placebo.
Topline data is expected in mid-2023.
Price Action: RVPH shares are up 2.72% at $4.15 during the premarket session on the last check Thursday.